Skip to main content

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Research Question:
Is ATA188 effective as a therapy for those with progressive multiple sclerosis?

Basic Study Information

The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]).

Location: University of Rochester Medical Center
Study Reference #: 00005559

Lead Researcher (Principal Investigator)

Lead Researcher:  Andrew Goodman

Study Contact Information

Study Coordinator: Jennifer Voelkl
Phone: (585) 276-3513

Additional Study Details

Return to Search